Extracorporeal membrane oxygenation (ECMO) is a life-saving support system used in neonates and young children with severe cardiorespiratory failure. Although ECMO has reduced mortality in these critically ill patients, almost all patients treated with ECMO develop a systemic inflammatory response syndrome (SIRS) characterized by a 'cytokine storm', leukocyte activation, and multisystem organ dysfunction. We used a neonatal porcine model of ECMO to investigate whether rising plasma concentrations of inflammatory cytokines during ECMO reflect de novo synthesis of these mediators in inflamed tissues, and therefore, can be used to assess the severity of ECMO-related SIRS. Previously healthy piglets (3-week-old) were subjected to venoarterial ECMO for up to 8 h. SIRS was assessed by histopathological analysis, measurement of neutrophil activation (flow cytometry), plasma cytokine concentrations (enzyme immunoassays), and tissue expression of inflammatory genes (PCR/western blots). Mast cell degranulation was investigated by measurement of plasma tryptase activity. Porcine neonatal ECMO was associated with systemic inflammatory changes similar to those seen in human neonates. Tumor necrosis factor-alpha (TNF-a) and interleukin-8 (IL-8) concentrations rose rapidly during the first 2 h of ECMO, faster than the tissue expression of these cytokines. ECMO was associated with increased plasma mast cell tryptase activity, indicating that increased plasma concentrations of inflammatory cytokines during ECMO may result from mast cell degranulation and associated release of preformed cytokines stored in mast cells. TNF-a and IL-8 concentrations rose faster in plasma than in the peripheral tissues during ECMO, indicating that rising plasma levels of these cytokines immediately after the initiation of ECMO may not reflect increasing tissue synthesis of these cytokines. Mobilization of preformed cellular stores of inflammatory cytokines such as in mucosal mast cells may have an important pathophysiological role in ECMO-related SIRS. Extracorporeal membrane oxygenation (ECMO) is used for providing cardiopulmonary support in critically ill neonates and young children with respiratory failure, congenital heart disease, and overwhelming sepsis. Although the availability of ECMO has reduced mortality in these patients by nearly 80%, concerns remain about the near-universal occurrence of a systemic inflammatory response syndrome (SIRS) during ECMO that is associated with multisystem organ dysfunction and considerable morbidity. This inflammatory response usually manifests within the first few hours of ECMO with hypotension, decreased urine output, decreased lung compliance, anasarca, and liver dysfunction, changes that frequently persist for several days and delay recovery from the underlying disease that led to ECMO in the first place.
Extracorporeal membrane oxygenation (ECMO) is used for providing cardiopulmonary support in critically ill neonates and young children with respiratory failure, congenital heart disease, and overwhelming sepsis. Although the availability of ECMO has reduced mortality in these patients by nearly 80%, concerns remain about the near-universal occurrence of a systemic inflammatory response syndrome (SIRS) during ECMO that is associated with multisystem organ dysfunction and considerable morbidity. This inflammatory response usually manifests within the first few hours of ECMO with hypotension, decreased urine output, decreased lung compliance, anasarca, and liver dysfunction, changes that frequently persist for several days and delay recovery from the underlying disease that led to ECMO in the first place. [1] [2] [3] Elucidation of the mechanisms of ECMO-related SIRS is a critical step in the development of effective anti-in-flammatory strategies, which may prevent adverse effects and thereby reduce the average duration of ECMO, encourage its institution earlier in the clinical course of cardiorespiratory failure rather than as a 'rescue' therapy of last resort, and possibly allow its application in a wider range of indications. 1, 3 Extracorporeal membrane oxygenation-related inflammatory complications are more frequent in younger patients. Neonates and young infants are at greater risk because the enormous disparity between the patient's circulating blood volume and that of the circuit (circuit volumes are often 200-300% greater than patient's circulating blood volume) increases the activation of various blood components on exposure to the foreign surface of the ECMO circuit. 4, 5 The high incidence of ECMO-related complications in neonates is not altered by the configuration (venoarterial vs venovenous) of ECMO or by the underlying cause of cardiorespiratory failure; 6 developmental factors such as high metabolic demands, reactivity of the pulmonary vasculature, and immaturity of vascular autoregulation are believed to be more important. 5 Our understanding of the inflammatory effects of extracorporeal circulation is primarily based on studies on adult patients treated with cardiopulmonary bypass (CPB) during cardiac surgery. 7, 8 However, the extrapolation of data from CPB to ECMO is difficult because of major pathophysiological differences between the two modalities, such as the presence of defined ischemia-reperfusion sequences in CPB (related to the placement and release of aortic cross-clamps during cardiac surgery) but not in ECMO. 9, 10 In this study, we used a porcine neonatal model of ECMO to investigate the hypothesis that rising plasma concentrations of inflammatory cytokines during ECMO reflect de novo synthesis of these mediators in inflamed tissues, and therefore, can be used to assess the severity of ECMO-related SIRS. We subjected previously healthy piglets weighing 3-6 kg to venoarterial ECMO in the laboratory and detected inflammatory changes that were similar to those seen in human neonates. However, plasma concentrations of tumor necrosis factor-alpha (TNF-a) and interleukin-8 (IL-8, CXCligand 8 (CXCL8)) increased within the first 2 h of ECMO, faster than the increase in tissue expression of these cytokines. These findings indicated that the increased plasma concentrations of inflammatory cytokines could not be completely explained on the basis of increased de novo synthesis in inflamed tissues and may have resulted, at least partially, from redistribution of preformed stores of these cytokines. Plasma TNF-a and IL-8 levels correlated with plasma mast cell tryptase activity, indicating that mast cell degranulation may contribute to the rapid rise of plasma cytokine concentrations during ECMO.
METHODS

Neonatal Porcine ECMO Animals
Mixed-breed neonatal piglets of either gender weighing 3-6 kg were subjected to venoarterial ECMO after approval by the UAB Institutional Animal Care and Use Committee. Sham animals received anesthesia, assisted ventilation, vascular cannulation, and heparinization similar to ECMO animals, but were not connected to the circulatory pump device. Data in this study represent eight animals each in sham and ECMO groups; three animals in each group were euthanized after 2 h of treatment and the remaining five after 8 h.
Anesthesia, assisted ventilation and baseline support
The piglets were anesthetized with intramuscular atropine (0.04 mg/kg), tiletamine HCl/zolazepam HCl (4.4 mg/kg), and xylazine (4.4 mg/kg). All animals were intubated with a size 3.5 cuffed endotracheal tube and mechanically ventilated (volume controlled, tidal volume ¼ 15 ml/kg, Hallowell EMC 2000 veterinary anesthesia ventilator) at a rate of 10-15 cycles/min with the pig in a dorsally recumbent position. Anesthesia was maintained by inhalation of isoflurane (1.5-2.5%) administered in 100% oxygen. Surface lead II EKG recordings, arterial blood pressure (ABP), and core (rectal) temperature was monitored. Water-heated pads were used to maintain normothermia (37±11C). Serum electrolyte levels and arterial blood gases were monitored throughout the study. Animals were given intravenous 0.9% saline at 2-5 ml/kg/h during the experiment and also provided boluses as required to maintain normal ABP.
Vascular access
A multiple side-hole 8-10 F Biomedicus venous cannula (Medtronic Perfusion Systems, Minneapolis, MN, USA) was inserted into the external jugular vein and advanced into the right atrium. The common carotid artery was cannulated using a 6-8 F Biomedicus arterial cannula. Placement of these cannulae was confirmed by fluoroscopy.
Heparinization
After circuit priming and before starting ECMO, animals were bolused with porcine heparin (Sigma, St Louis, MO, USA; 150 U/kg), followed by additional intravenous heparin injections to maintain activated clotting times of 180-220 s after the initiation of ECMO.
ECMO procedure
Extracorporeal membrane oxygenation circuit was primed with 1 l 0.9% saline followed by 300 ml porcine whole blood collected from a similarly anesthetized pig, 10 ml sodium bicarbonate, 1500 U of porcine heparin, and 50 mg calcium chloride. The venoarterial ECMO system consisted of a Biomedicus BP-50 centrifugal pump (Medtronic, Shoreview, MN, USA), and a Minimax hollow fiber oxygenator (Medtronic) with an integral heat exchanger. Water bath temperatures were maintained at 371C using a Sarns Dual Heater/Cooler (Soma Technology, Cheshire, CT, USA). Gas flow rates to the membrane oxygenator were maintained at 0.5 l/min of 100% oxygen. After starting ECMO, the flow rates in the circuit were advanced to 350 ml/min or 1.5 l/min/m 2 . Additional volume requirements to maintain circuit flow or desired hemoglobin level were met by the addition of a porcine whole blood or saline boluses. Animals were euthanized after 2 or 8 h of ECMO by administration of potassium chloride.
Neutrophils
Neutrophils were isolated using an established densitycentrifugation method. 11 Briefly, porcine blood was mixed with 4% gelatin (Sigma) in 0.9% NaCl and allowed to settle at 371C for 30 min. The supernatant was then layered over Histopaque-1083 separation media (Sigma) and centrifuged at 400 g for 25 min at room temperature. Neutrophils were isolated from the resultant pellet after hypotonic lysis of the red blood cells and suspended in Hanks' balanced salt solution (Sigma). 12 Cells were suspended in RPMI-1640 supplemented with 10% fetal bovine serum and antibiotics.
Histopathological Analysis and Immunohistochemistry
Harvested tissues were fixed in formalin and embedded in paraffin. Histopathological examinations were performed on hematoxylin-eosin stained sections. Paraffin-embedded tissue sections were immunostained for c-kit (CD117, a mast cell marker), TNF-a, and IL-8/CXCL8 as previously described. 12, 13 Briefly, tissue sections were deparaffinized with xylene and graded ethanols and antigen retrieval was achieved by heating the sections in 10 mM sodium citrate buffer, pH 6.0 at 951C Â 10 min followed by treatment with proteinase K (20 mg/ml; Sigma) at 371C Â 20 min. After blocking overnight (Superblock, Pierce, Rockford, IL, USA), the sections were stained overnight (4 o C) with primary antibodies (mouse antibodies against c-kit and goat antibodies against TNF-a, and IL-8 from Santa Cruz Biotechnology, Santa Cruz, CA, USA). Secondary staining was performed at room temperature for 30 min with Alexa 488-and/or Alexa 568-conjugated donkey anti-goat IgG and rabbit anti-mouse IgG (Invitrogen, San Diego, CA, USA). Controls included slides with no primary antibody and appropriate isotype control. The cell nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (Calbiochem, San Diego, CA, USA), diluted 1:1000 in PBS, applied for 3 min. Imaging was performed using a fluorescence microscope (Carl Zeiss Microimaging, Thornwood, NY, USA).
Flow Cytometry
Neutrophils were stained for neutrophil activation markers CD18, CD35, CD62L, and CD11b using our previously reported protocol.
14 Controls included cells with no antibody and appropriate isotype control.
Real-Time PCR Real-time PCR was carried out using our previously described protocol.
14 Total RNA was isolated using the acid guanidinium thiocyanate-phenol-chloroform extraction protocol (Trizol reagent, Invitrogen). First-strand cDNA was synthesized using oligo-dT primers and Moloney murine leukemia virus reverse transcriptase (Invitrogen). Real-time PCR primers were designed using the Beacon Design software (Bio-Rad, Hercules, CA, USA). Two-step real-time PCR was carried out using a SYBR Green protocol described elsewhere.
14 Data were normalized against glyceraldehyde-3-phosphate dehydrogenase and gene expression was compared between samples by using the 2 -DDCT method.
ELISA Plasma concentrations of porcine cytokines TNF-a, IL-8/ CXCL8, IL-6, and IL-1b were measured by enzyme-linked immunosorbent assay (ELISA) (R&D systems, Minneapolis, MA, USA). ELISA kits for porcine CRP and C5a were purchased from Alpco Diagnostics, Salem, NH, USA, and Immuno-biological Laboratories, Minneapolis, MN, USA, respectively.
Western Blots
Western blots were performed for TNF-a using our previously described protocol 14 and were analyzed using the NIH scion software.
Measurement of Mast Cell Degranulation
We used a commercially available assay (Millipore, Bedford, MA, USA) based on the spectophotometric detection (405 nm) of a chromophore p-nitroaniline (pNA) released by tryptase action on a labeled substrate tosyl-gly-pro-lys-pNA.
Archived Tissues from Human Neonates Treated with ECMO
Autopsy samples from full-term human neonates who died during treatment with ECMO for pulmonary hypertension (n ¼ 3) were obtained with approval of the local Institutional Review Board.
Statistical Methods
Parametric and nonparametric tests were applied using the SigmaStat 3.1.1 software (Systat, Point Richmond, CA, USA). The number of samples and the statistical analyses are described in the figure legends. A P-value of o0.05 was considered significant.
RESULTS
Hemodynamic Changes During ECMO
The ECMO animals developed tachycardia and hypotension within 1-2 h of initiation of ECMO. We treated hypotension with intravenous boluses of normal saline or porcine wholeblood transfusions (given if hematocrit was o20%). In the ECMO group, capillary leakiness became clinically evident by about 4 h of ECMO with abdominal distension due to ascites. Animals subjected to ECMO needed more frequent fluid boluses and blood transfusions (total administered volume 18±9 ml/kg in sham animals vs 178±16 ml/kg in animals treated with ECMO, Po0.05). The vital parameters of animals in sham and ECMO groups did not differ from each other.
Histopathological Evidence of Inflammation
Leukocyte infiltration, focal hemorrhages, and/or edema were evident in most tissues examined, including the lung, intestine, liver, skin, and kidney after 2 h of ECMO. These inflammatory changes increased in severity after 8 h. These changes were most prominent in the lung and the intestine (Figure 1a) . These histopathological changes of inflammation in our porcine model were generally similar to changes noted in autopsy tissue samples from human neonates who died during ECMO (Figure 1b) . Although the contribution of the underlying illness (that led to cardiopulmonary failure) to the inflammatory changes in these neonates cannot be clearly ascertained, these findings provide indirect evidence for our observations in the porcine model.
Neutrophil Activation During ECMO
As neutrophil activation is a key event during human ECMO, 15, 16 we measured the expression of CD18, CD35, CD62L, and CD11b on circulating neutrophils in hourly samples from sham and ECMO animals by flow cytometry. Compared with sham animals, the expression of all four activation markers was significantly upregulated in ECMO animals. The expression of these markers at 2 h (time point chosen to compare with histopathological changes of inflammation) is depicted in Figure 1c .
Porcine ECMO was Associated with a 'Global' Activation of Proinflammatory Genes Using a real-time PCR microarray, we next measured mRNA expression of 48 well-characterized porcine inflammatory genes in lung and intestinal tissue. As shown in Figure 2a , we detected increased expression of neutrophil chemokines IL-8/ CXCL8 and growth-related oncoprotein-b/CXCL2 and mononuclear cell chemokines interferon-inducible protein-10/CXCL10, CXCL12, macrophage inflammatory protein-1b/ CC-ligand 4, CCL11, and CCL21. Inflammatory cytokines, such as TNF-a, interferon-g, IL-1b, IL-6, IL-12, IL-15, and IL-18 were also upregulated. We also found increased tissue expression of the cognate receptors for TNF-a (TNF-receptor II), IL8 and GRO-b/CXCL2 (CXC receptors CXCR1 and CXCR2), CXCL10 (CXCR3), and MIP-1b/CCL4 (CCR3). The expression of nuclear factor-kB and activator protein 1 transcription factors was also increased. These changes showed that ECMO activated a wide range of proinflammatory genes encoding for important chemokines, cytokines, cytokine/chemokine receptors, and critical transcriptional factors that regulate the expression of these cytokines and chemokines.
Increased Plasma Concentrations of Proinflammatory Cytokines
In support of the data obtained from the PCR array shown in Figure 4a , we compared the plasma concentrations of TNF-a, IL-8, IL-6, and IL-1b in sham and ECMO animals. We detected a rapid rise in plasma levels of TNF-a and IL-8 within the first 2 h of ECMO, which was not observed in sham-treated animals (Figure 2b ). Plasma IL-1b and IL-6 levels increased more slowly, rising significantly after 4-6 h of ECMO.
Onset of Systemic Inflammatory
9 /l at 4 h of treatment in sham vs ECMO animals, respectively (differences not statistically significant). The absolute neutrophil counts were also not affected by ECMO (8.9 ± 1.2 Â 10 9 /l vs 7.85 ± 2.1 Â 10 9 /l in sham and ECMO animals, respectively). Similarly, plasma CRP concentrations were also not altered by ECMO-related SIRS (Figure 3 ). Other acute-phase reactants, such as erythrocyte sedimentation rate and fibrinogen levels, were considered but not evaluated during ECMO because of the presence of multiple confounding factors such as transfusions and heparinization.
Rapid rise in plasma TNF-a and IL-8 levels during ECMO is not matched by increased synthesis of these cytokines in the tissues To investigate whether increased plasma concentrations of TNF-a and IL-8 during ECMO reflect increased de novo synthesis of these cytokines in inflamed tissues, we next measured mRNA and protein expression for TNF-a and IL-8 in tissues harvested from sham and ECMO animals after 2 h of treatment. Although the mRNA expression of TNF-a increased in various tissues at 2 h of ECMO (Figure 4a ), we did not detect important differences in TNF-a protein that could explain the rise in plasma TNF-a concentrations during ECMO at this time point. In contrast to the eightfold increase in plasma TNF-a concentration at 2 h of ECMO, TNF-a expression was decreased in the intestine and increased 1.5-to 2-fold in tissue samples from the liver and spleen (Figure 4b) . Similarly, we measured a 0.9-to 5-fold change in IL-8 mRNA in the tissues but the amount of IL-8 protein did not increase significantly in the tissues after 2 h of ECMO; the expression of IL-8 was also decreased in the intestine at the 2-h time point (Supplementary Figure 1) . Figure 1 Histopathological changes of inflammation during extracorporeal membrane oxygenation (ECMO). (a) Hematoxylin-eosin (H&E)-stained sections from the lung and the intestine (jejunum) after 2 and 8 h of ECMO. Upper panel: Histopathological changes after 2 h of ECMO. Photomicrographs (magnification Â 100) highlight the differences between the near-normal alveolar histoarchitecture in sham animals vs the conspicuous leukocyte infiltration and focal hemorrhages in ECMO. In the intestine, ECMO caused an increase in cellularity in the lamina propria (low magnification), which was due to leukocyte infiltration (higher magnification inset). Data represents n ¼ 3 animals in both groups. Lower panel: Histopathological changes after 8 h of ECMO. Inflammatory changes in the lung became worse with increased leukocyte infiltration, hemorrhages, and septal edema. In the intestine, there was an increase in leukocyte infiltration (black arrows) and focal hemorrhages. The epithelium was disrupted (magnification Â 100). Insets show high-magnification photomicrographs ( Â 400) highlighting the inflammatory changes. Data represent n ¼ 5 animals in both groups. (b) Photomicrographs of the lung and jejunum from human neonates who died during ECMO, showing the marked similarity between inflammatory changes in our porcine model and human tissues. Upper panel shows the effect of ECMO on the lung, including leukocyte infiltration and alveolar hemorrhages. Lower panel shows marked leukocyte infiltration and disruption of the epithelium in the intestine. Data represent three neonates. (c) Neutrophil activation during neonatal porcine ECMO. Representative FACS histograms from sham and ECMO animals drawn after 2 h of treatment show increased expression of activation markers CD18, CD35, CD62L, and CD11b on circulating neutrophils during ECMO. Bar diagrams shown below the FACS panels summarize the information from an n ¼ 5 in both groups. Data were analyzed by the Mann-Whitney U-test. Asterisk (*) indicates a significant difference between ECMO and sham groups, Po0.05.
Mast Cells Contain Preformed TNF-a
As the rapid rise in plasma TNF-a and IL-8 levels during ECMO could not be explained on the basis of increased de novo synthesis of these cytokines, we next investigated whether ECMO mobilized preformed tissue stores of TNF-a and IL-8 into the plasma. As seen in the western blots in Figure 4b , the intestine contained the largest amounts of TNF-a in control animals. These data were consistent with evidence that mast cells present in mucosal organs such as the intestine comprise the largest store of preformed TNF-a in the body 17, 18 and have an important role in experimental models of SIRS. 19 In Figure 4b , the reduction in TNF-a in the ECMO intestine was also consistent with the hypothesized release of cellular stores during ECMO. Therefore, we first used immunofluorescence microscopy to confirm whether porcine mucosal mast cells contained TNF-a. As seen in Figure 5a , strong immunoreactivity for TNF-a was detected in c-kit þ mast cells in the intestine in both sham and ECMO animals. We also detected TNF-a in mast cells in sham/ECMO porcine lung, although the lung contained fewer mast cells than the intestine (not depicted). Mast cells also showed strong immunoreactivity for IL-8 in both sham and ECMO animals (not depicted). To confirm the pathophysiological relevance of mast cells in ECMO-related SIRS in human neonates, we also stained intestinal tissues from human neonates treated with ECMO (autopsy samples); a similar colocalization of c-kit and TNF-a was detected (Figure 5b ).
ECMO is Associated with Degranulation of Mast Cells
To investigate whether the initiation of ECMO in our porcine model was associated with mast cell degranulation, we next compared plasma samples from sham and ECMO animals for tryptase (mast cell protease 7) activity, a serine protease present almost exclusively and in large amounts in mast cell granules. 20, 21 As shown in Figure 5c , plasma tryptase activity after 1 h of ECMO was nearly fourfold higher than in sham animals and correlated with plasma concentrations of TNF-a and IL-8/CXCL8 (Po0.05). Mast cell degranulation is a plausible event during ECMO because activation of the complement pathway in the membrane oxygenator releases several mast cell secretagogues, such as C5a, C3a, and C3adesArg. 22 Consistent with this hypothesis, we detected increased plasma C5a levels in our porcine model after 1 h of ECMO (inset, Figure 5c ).
DISCUSSION
The histopathological changes of inflammation, activation of neutrophils, and increased plasma concentrations of various proinflammatory cytokines in our piglet model were generally similar to those reported in human ECMO. 16, [23] [24] [25] Existing clinical and experimental evidence on the mechanisms of ECMO-related SIRS emphasizes the activation of neutrophils and other leukocytes as a pivotal event during ECMO, which occurs due to contact with the foreign surface of the circuit, shear stress, expression of inflammatory cytokines, activation of complement, coagulation and fibrinolytic pathways, and increased concentrations of bioactive lipids. 16, [22] [23] [24] [25] [26] [27] [28] These activated neutrophils adhere to the capillary/venular endothelium and undergo degranulation to produce cytokines, arachidonic acid metabolites, and reactive oxygen species, causing widespread microvascular injury 15, 27 and multiorgan dysfunction. 16, [22] [23] [24] [25] [26] [27] [28] The rapid rise in plasma concentrations of TNF-a and IL-8 almost immediately after the initiation of ECMO suggests that these cytokines may be important mediators in the development of ECMO-related inflammation. TNF-a can induce the expression of a wide range of inflammatory genes, including its own, 29 which suggests that the early rise in circulating TNF-a levels during ECMO may form a 'feedforward' loop to augment the inflammatory responses.
In human neonates, higher plasma TNF-a concentrations have been noted in patients who died during ECMO than in 'responders' who recovered completely. 16, 26, 30 In other studies, plasma concentrations of IL-8 correlated with the severity of SIRS and cardiopulmonary impairment during ECMO. 16, 23, 24, 31 The marked elevation in plasma cytokine levels in our model contrasted with the low sensitivity of acute-phase reactants, such as leukocyte counts and plasma CRP concentrations. Elevated CRP levels have been noted in one previous report on human ECMO 31 in which CRP concentrations were higher in nonresponders as compared with patients who improved on ECMO, although CRP was found to be less sensitive as a prognostic indicator than IL-6. The differential expression of IL-6 and CRP in our model was Figure 3 Onset of systemic inflammatory response during extracorporeal membrane oxygenation (ECMO) was not reflected in plasma C-reactive protein concentrations during ECMO. Unlike the marked changes seen in plasma cytokine concentrations, we did not detect significant changes in plasma CRP in the initial 8 h of ECMO. Other acute-phase reactants such as leukocyte counts were also not discriminatory (not depicted). Line diagrams (means ± s.e.m.) summarize information from five animals each in ECMO and sham groups. Data were analyzed by the repeated measures ANOVA on ranks. surprising because IL-6 is a potent inducer of CRP production in the liver and the two mediators are usually identified as bound variables in various inflammatory states. 32 A possible explanation may be related to the 8-h duration of our experiments, in which we might have missed a late rise in plasma CRP concentrations (following the delayed rise in IL-6 levels). Alternatively, the CRP response may have been dampened by the relative resistance of porcine hepatocytes to IL-6, a species-specific feature. IL-6 induces CRP expression in hepatocytes through a CCAAT-enhancer binding proteinbeta (C/EBP-b)-mediated pathway, 33 which carries unique post-translational modifications and/or compartmentalization of C/EBP-b in pigs. 34 The increase in plasma TNF-a and IL-8 concentrations within 2 h of initiation of ECMO in our model was not associated with a proportionate increase in the tissue synthesis of these cytokines at the same time. Considering the rapid change in plasma cytokine levels and also because the expression of TNF-a protein was actually decreased in the intestine at 2 h, we hypothesized that ECMO mobilized these cytokines from preformed tissue stores of TNF-a into plasma. Of all the major cellular sources of TNF-a, mast cells 35 and eosinophils 36 are the only cell types considered capable of storing preformed TNF-a. We focused on mast cells and not eosinophils in this study because the gut mucosa normally contains a large reservoir of mast cells. 17, 18 The plausibility of mast cell degranulation, as shown in our model, is supported by existing data on the activation of complement and consequent release of mast cell secretagogues, such as C5a, C3a, and C3adesArg during human ECMO.
37 C3a levels have also been shown to correlate with plasma TNF-a levels and the severity of inflammation during ECMO. 30 Mast cells are now increasingly recognized as a major source of preformed TNF-a in SIRS in diverse settings, such as in Gram-negative and Gram-positive bacterial sepsis, peritonitis, severe alveolar hypoxia, and portal hypertension. [38] [39] [40] [41] [42] Unlike other major cellular sources of TNF-a such as macrophages and T-/B-lymphocytes that contain little or no detectable TNF-a unless appropriately stimulated, 43, 44 mast cells present in mucosal organs contain large amounts of preformed TNF-a 17, 18 and have an important role in experimental models of SIRS. 19 Histamine liberation has been previously reported during CPB in older children and adults, but circulating basophils, and not mast cells, were incriminated as the source. 45, 46 As we mentioned earlier, mechanistic differences in the inflammatory responses associated with ECMO vs CPB are not unexpected and illustrate the need for specifically directed studies for these two forms of ECC. Even though ECMO and CPB are both performed using similar circulatory pumps and other major equipment, CPB is associated with several additional pathophysiological variables such as ischemia-reperfusion injury from aortic cross-clamping and due to the vasoconstrictive effects of hypothermia and hemodilution, proinflammatory effects of surgical trauma and tissue debris, and more frequent use of protamine. 7, 8, [47] [48] [49] In conclusion, the institution of ECMO in our porcine model induced systemic inflammatory changes that were remarkably similar to those reported during human ECMO. Although our original hypothesis that increased plasma TNF-a/IL-8 levels reflect tissue synthesis of these cytokines during ECMO was disproven, our data reaffirmed the higher sensitivity of inflammatory cytokines as indicators of inflammation during ECMO as compared with blood leukocyte counts and C-reactive protein. Further studies are needed to develop a panel of cytokines that are synthesized de novo during ECMO-related SIRS and not released from preformed stores. We have also identified mast cell degranulation and the release of TNF-a as early events in ECMO-related SIRS. The availability of agents that can stabilize enteric mast cells 50 , as well as effective neutralizing anti-TNF-a antibodies raises important therapeutic possibilities 51 and indicates a need to aggressively investigate these targets in preclinical and clinical settings. shows that plasma samples after 1 h of ECMO contained high levels of C5a, a potent mast cell secretagogue released during activation of the complement pathway. Data were analyzed by the Mann-Whitney U-test. Asterisk (*) indicates a significant difference between ECMO and sham groups, Po0.05.
